Abbhi Capital

Clinical Research IO is a health technology company that specializes in developing software for clinical research sites. The company offers an electronic source (eSource) platform that allows research investigators to create customizable templates for capturing clinical trial data using mobile devices, thereby enhancing efficiency and accuracy in the data collection process. The software includes modules for patient recruitment, scheduling, and compliance management, which feature tools for sending text reminders to patients. Additionally, Clinical Research IO integrates its eSource with a Clinical Trial Management System (CTMS) that facilitates the management of regulatory documents electronically. With offices in Boston and San Francisco, the company aims to modernize the traditionally paper-based clinical trial process.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient’s own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.